You are here

Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
UCLA Ronald Reagan Medical Center
Los Angeles, California, 90095 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Cerebral Amyloid Angiopathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
55-90 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients diagnosed with probable CAA using the Boston criteria; with no clinical
cognitive impairment

- In general good health

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Co-morbid diagnosis of clinically documented Alzheimer's disease or significant
cognitive impairment

- Clinically significant syncope, epilepsy, head trauma or clinically significant
unexplained loss of consciousness within the last 5 years

- Subject's body weight exceeding 100kg

- Women of childbearing potential.

NCT01821118
Pfizer
Completed
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now